BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 10557309)

  • 1. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.
    Khan J; Bittner ML; Saal LH; Teichmann U; Azorsa DO; Gooden GC; Pavan WJ; Trent JM; Meltzer PS
    Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13264-9. PubMed ID: 10557309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
    Sublett JE; Jeon IS; Shapiro DN
    Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
    Barr FG
    Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
    Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
    Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
    Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
    Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
    Bennicelli JL; Edwards RH; Barr FG
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal and rearranged PAX3 expression in human rhabdomyosarcoma.
    Frascella E; Toffolatti L; Rosolen A
    Cancer Genet Cytogenet; 1998 Apr; 102(2):104-9. PubMed ID: 9546061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis.
    Graf Finckenstein F; Shahbazian V; Davicioni E; Ren YX; Anderson MJ
    Oncogene; 2008 Mar; 27(14):2004-14. PubMed ID: 17922034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.
    Davis RJ; Barr FG
    Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8047-51. PubMed ID: 9223312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
    Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma.
    Barr FG; Nauta LE; Davis RJ; Schäfer BW; Nycum LM; Biegel JA
    Hum Mol Genet; 1996 Jan; 5(1):15-21. PubMed ID: 8789435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.
    Lam PY; Sublett JE; Hollenbach AD; Roussel MF
    Mol Cell Biol; 1999 Jan; 19(1):594-601. PubMed ID: 9858583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
    Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ
    Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells.
    Calhabeu F; Hayashi S; Morgan JE; Relaix F; Zammit PS
    Oncogene; 2013 Jan; 32(5):651-62. PubMed ID: 22710712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein.
    Xia SJ; Barr FG
    Oncogene; 2004 Sep; 23(41):6864-71. PubMed ID: 15286710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain.
    Zhang L; Wang C
    Oncogene; 2007 Mar; 26(11):1595-605. PubMed ID: 16964289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pax7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD.
    Olguín HC; Patzlaff NE; Olwin BB
    J Cell Biochem; 2011 May; 112(5):1410-7. PubMed ID: 21321994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.
    Scheidler S; Fredericks WJ; Rauscher FJ; Barr FG; Vogt PK
    Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9805-9. PubMed ID: 8790412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
    Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
    Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma.
    Kempf BE; Vogt PK
    Cell Growth Differ; 1999 Dec; 10(12):813-8. PubMed ID: 10616906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.